Skip to content
香港聯合腫瘤中心
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En

Category: 免疫治療

NCT06966700: Trofuse-032/MK2870-032 Research

Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with high-risk early-stage triple-negative breast cancer (TNBC) or hormone receptor-weak positive/HER2-negative breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the criteria for participation in this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.

立即閱讀
November 19, 2025 No Comments

NCT06899126: Destiny-lung 06 Research

The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with locally advanced, unresectable, or metastatic HER2-overexpressing non-squamous non-small cell lung cancer with PD-L1 TPS < 50%, please contact us. We will conduct an initial assessment to determine your eligibility for this clinical trial. Medication and imaging scans are free. However, patients must understand the purpose of the study and any potential risks.

立即閱讀
November 19, 2025 No Comments
Retifanlimab-dlwr治療默克爾細胞癌的突破性療效

Retifanlimab-dlwr is used to treat metastatic or recurrent locally advanced Merkel cell carcinoma

The U.S. FDA accelerated the approval of the PD-1 antibody retifanlimab-dlwr for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma in March 2023. The POD1UM-201 clinical trial showed a 52% objective remission rate, bringing new treatment options to patients with this rare skin cancer. Understand medication recommendations, safety data, and treatment precautions.

立即閱讀
September 21, 2025 No Comments
DURIGAST試驗FD組與FDT組療效對比數據表格，顯示4個月無進展生存率、中位PFS、客觀緩解率、中位OS及1年以上疾病控制率

Immunotherapy combined with chemotherapy for the treatment of advanced gastric cancer/gastroesophageal junction adenocarcinoma: Analysis of the results of DURIGAST PHASE II trial

研究概況 法國多中心非對照II期臨床試驗（PRODIGE 59-FFCD 1707-DURIGAST）評估了FOLFIRI方案聯合PD-L1抑制劑du

立即閱讀
September 15, 2025 No Comments
FDA批准retifanlimab-dlwr治療默克爾細胞癌新聞圖片

The U.S. FDA accelerated the approval of Retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma

The U.S. FDA accelerated the approval of the PD-1 inhibitor Retifanlimab-dlwr (Zynyz) for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma on March 22, 2024. The PODIUM-201 clinical TRIAL showed a 52% OBJECTIVE REMISSION rate, providing new treatment options for patients with rare skin CANCER. The United Cancer Centre of Hong Kong provides professional consulting services.

立即閱讀
September 9, 2025 No Comments
本組圖片詳細展示FDA最新批准的Tarlatamab-dlle治療廣泛期小細胞肺癌的重要資訊，包括藥物作用機制、臨床試驗數據分析、患者緩解率統計，以及香港癌症治療中心提供的專業醫療服務場景，為患者和家屬提供全面的治療資訊參考。

The U.S. FDA accelerated the approval of Tarlatamab-dlle for the treatment of broad-stage small cell lung cancer

The U.S. FDA accelerated the approval of Tarlatamab-dlle (trade name Imdelltra) for the treatment of extensive small cell lung cancer on May 16, 2024, bringing new hope to patients who have progressed after platinum chemotherapy. This innovative bispecific T-cell adapter showed excellent efficacy in the DeLLphi-301 clinical trial, with an objective remission rate of 40% and a median remission duration of 9.7 months. The drug effectively activates the patient's own immune system to attack cancer cells by targeting DLL3 and CD3. It is worth noting that the Hong Kong Department of Health has also recently approved the registration of related new drugs for the treatment of diffuse small cell lung cancer, indicating Hong Kong's positive progress in integrating the field of cancer treatment with international standards. For patients and their families in need, the professional team of the Hong Kong United Cancer Centre (HKUOC) can provide detailed medical consultations to help formulate the most suitable personalized treatment plan and grasp the golden opportunity for treatment.

立即閱讀
September 5, 2025 No Comments
香港聯合腫瘤中心李宇聰醫生講解肺癌治療新趨勢

Sing Tao Front Page Exclusive Interview: 55% of New Lung Cancer Cases Are at Advanced Stages, Personalized Therapy Helps Reduce Recurrence Risk

Sing Tao Headline invited Dr. Li Yu Chung, Jacky to analyze the trend of lung cancer treatment. In 2022, 55% of new lung cancer diseases have reached stage 4, with a survival rate of 72.4% in stage 1 vs. 24.6% in stage 3. The United Cancer Centre of Hong Kong provides personalized lung cancer treatment options guided by genetic testing to help reduce the risk of recurrence, improve treatment effectiveness and early screening success rate.

立即閱讀
August 21, 2025 No Comments
香港聯合腫瘤中心李宇聰醫生講解肺腺癌4期治療方案

TOPick Exclusive Interview: New Breakthrough in Stage 4 Lung Adenocarcinoma Treatment – Third-Generation Targeted Therapy Extends Survival by 38.6 Months

經濟日報TOPick邀請李宇聰醫生分析肺腺癌治療方案。第三代標靶藥整體存活期中位數達38.6個月，新型ADC標靶藥對無吸煙史患者有效率高達90%。香港聯合腫瘤中心提供個人化肺癌治療方案，助您了解最新治療突破及篩檢建議。

立即閱讀
August 20, 2025 No Comments
早期肺癌診斷與治療講座 - 香港聯合腫瘤中心（HKUOC）李宇聰醫生分享肺癌篩檢與治療方案

Diagnosis and treatment of early-stage lung cancer｜Cancer Lecture series (2025/06/06｜Invited by HKHCA)

On June 6, 2025, Dr. Li Yu Chung, Jacky, a specialist in the Department of Clinical Oncology at the Hong Kong United Oncology Centre (HKUOC), was invited by the Hong Kong Healthcare Alliance (HKHCA) to deliver a lecture titled Early Lung Cancer: Diagnosis and Treatment. He shared the latest information on lung cancer screening, symptoms of early-stage lung cancer, diagnostic procedures, and treatment options such as immunotherapy and targeted therapy regimens. The content is for health education purposes only and does not constitute medical advice. Treatment decisions should be made by a physician based on individual case assessments.

立即閱讀
August 19, 2025 No Comments
2025年肺癌治療新趨勢 - 李宇聰醫生於AIA講座分享

New trends in the treatment of lung cancer, breast cancer, and prostate cancer｜Patient Guide (Excerpted from AIA Internal Sharing｜2025/07/30)

2025年7月30日，香港聯合腫瘤中心（HKUOC）李宇聰醫生於AIA健康教育分享會講解肺癌、乳癌、前列腺癌治療新趨勢。包括標靶治療、免疫治療、ADC、SBRT及177Lu-PSMA等最新技術，僅供教育參考，助患者了解就醫重點與個人化治療方案。

立即閱讀
August 12, 2025 No Comments
Page1 Page2 Page3 Page4 Page5
香港聯合腫瘤中心

The Hong Kong United Oncology Centre (HKUOC) provides cancer-related medical services such as cancer screening, cancer diagnosis and cancer treatment, including immunotherapy, chemotherapy, targeted drug therapy, radiation therapy, hormone therapy and palliative care.

Contact us

  • Address: Rooms 01-06, 20/F, 238 Nathan Road, Kowloon (MTR Jordan Station Exit E)
  • Phone: +852 2386 8002
  • WhatsApp：5518 2992
  • Fax: (852) 2386 8229
  • Macau: Enquiry@hkuoc.hk

Consultation time

Monday to Friday

9:00 am to 1:00 pm

2:00 p.m. to 6:00 p.m.

Saturday

9:00 am to 1:00 pm

Closed on Sundays and public holidays

Types of cancer

  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer
  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer

Cancer treatment

  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy
  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy

phone

WhatsApp

Facebook